Loading
Pfizer Inc Stock: price and insider trades · United States
3 insiders bought €2.6M of shares over the last 90 days, the latest filed 12 Aug 2026.
Pfizer Inc: what insiders have been doing
Headquartered in New York City, United States, Pfizer Inc belongs to the Healthcare & Pharma sector and traces its origins to 1849. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 9 insiders published 17 filings.
Both sides are active: 3 purchases worth €2.6M and 2 sales worth €72k, from 3 insiders and 1 insider respectively. No amount is published for 1 filing, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 2 senior executives and 1 chief executive. At €867k, the purchase published on 12 August 2026 by Bourla Albert is the largest of the period (0.0006% of market cap).
In the case of 3 purchases, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The latest purchase dates back some time: it was published 67 days ago, on 12 August 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade.
Compared with its exchange (5,816 companies, median 19 filings), a count of 17 filings is below the norm. Looking back to 2016, when coverage begins, insiders filed 7 purchases and 18 sales. The 10-K for the year ended 31 December 2025 shows 62.58 bn USD of revenue and 7.77 bn USD of net income and a dividend of 1.72 USD per share.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
132
Thresholds
n/a
Buy Volume
€3M
7 ops. · all time
Sell Volume
€6M
18 ops. · all time
Who traded when
BuySaleJennifer B. Damico2 sales
Ronald E. Blaylock2 buys
Albert Bourla1 buy
Mortimer J. Buckley1 buy
Since the insiders bought
- +9.9%Entry US$26.80 · Close 15 Oct 2026 US$29.44
- +12.4%Entry US$26.20 · Close 15 Oct 2026 US$29.44
- +12.4%Entry US$26.20 · Close 15 Oct 2026 US$29.44
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Pfizer Inc Buy (bullish), based on 26 analysts. Average price target: US$29.26.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,249 of 24,148 companies
57.4
score / 100
Value56
Quality59
FCF yld5.4%
Earn yld4.6%
EV/EBITDA13.9x
ROE5.0%
Gross mgn74%
Net mgn12%
Debt/EBITDA3.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$29.21
Analyst consensus
26 analystsBuy
US$25.00Target US$29.26(+0%)US$36.00
Income statement
RevenueUS$62.6B
Gross profitUS$46.5B74% margin
EBITDAUS$16.8B27% margin
Net incomeUS$7.8B6.8% margin
Valuation
PER (trailing)38.4x
PER (forward)10.1x
P/Book2.0x
Beta0.28
Balance sheet & cash
Market capUS$166.5B
Total debtUS$64B
Free Cash FlowUS$9.1B
Debt / Equity74%
Profitability & ownership
ROE5.0%
ROA5.8%
% insiders0.1%
% institutions69.1%
Last declaration on 12 August 2026
Declarations132 total
38,000 shares@ US$26.340.0006% mcap1.6% of flowCommon StockSEC:0001225208-26-007083:0
Canonical exit: 10 Nov 2026 (T+90)
3,278 shares@ US$25.400.0001% mcap2.0% of flowCommon StockSEC:0001225208-26-007004:0
39,231 shares@ US$25.460.0006% mcap64.3% of flowCommon StockSEC:0001225208-26-006944:0
Canonical exit: 3 Nov 2026 (T+90)
37,632 shares@ US$25.520.0006% mcap100.0% of flowCommon StockSEC:0001225208-26-006943:0
Canonical exit: 3 Nov 2026 (T+90)
2,000 sharesCommon StockSEC:0001225208-26-005911:0
16,311 shares0Common StockSEC:0001225208-26-003318:0
655 shares@ US$27.650.4% of flowCommon StockSEC:0001225208-26-002921:0
56,888 shares@ US$33.8241.6% of flowCommon StockSEC:0001225208-26-002821:0
122,907 shares@ US$33.8215.7% of flowCommon StockSEC:0001225208-26-002820:0
37,925 shares@ US$33.8223.8% of flowCommon StockSEC:0001225208-26-002816:0
17,558 shares@ US$33.8214.1% of flowCommon StockSEC:0001225208-26-002819:0
491,626 shares@ US$33.8225.8% of flowCommon StockSEC:0001225208-26-002818:0
56,888 shares@ US$33.8239.7% of flowCommon StockSEC:0001225208-26-002817:0
13,383 shares0Common StockSEC:0001225208-26-002815:0
816 shares@ US$27.061.7% of flowCommon StockSEC:0001225208-26-002482:0
419 shares@ US$27.060.3% of flowCommon StockSEC:0001225208-26-002481:0
12,887 shares@ US$26.4425.5% of flowCommon StockSEC:0001225208-26-001126:0
749 shares@ US$26.100.5% of flowCommon StockSEC:0001225208-25-003073:0
403 shares@ US$26.650.9% of flowCommon StockSEC:0001225208-25-002701:0
48,419 shares@ US$31.3131.6% of flowCommon StockSEC:0001225208-25-002706:0
22,416 shares@ US$31.3118.7% of flowCommon StockSEC:0001225208-25-002710:0
156,914 shares@ US$31.3120.8% of flowCommon StockSEC:0001225208-25-002705:0
72,629 shares@ US$31.3152.7% of flowCommon StockSEC:0001225208-25-002704:0
582,823 shares@ US$31.3131.7% of flowCommon StockSEC:0001225208-25-002703:0
85,182 shares@ US$31.3119.5% of flowCommon StockSEC:0001225208-25-002708:0
25 of 132 declarations
About Pfizer Inc
Pfizer Inc. is a global biopharmaceutical company listed in the United States on the NYSE under the ticker PFE, with its global headquarters in New York, New York (United States). Founded in 1849 in Brooklyn by Charles Pfizer and Charles Erhart, Pfizer has evolved from a small chemical business into one of the world’s most recognized pharmaceutical groups. Its business model is centered on discovering, developing, manufacturing, and commercializing medicines and vaccines for major unmet medical needs.
Pfizer’s core operations are concentrated in innovative pharmaceuticals and vaccines, supported by capabilities in biologics and biosimilars. The company spans several major therapeutic areas, including oncology, rare disease, inflammation and immunology, internal medicine, infectious disease, and vaccines. Its portfolio includes a mix of established franchises and newer assets from ongoing R&D, allowing the company to balance near-term commercial cash flows with longer-term innovation. Well-known brands and platforms include the Prevnar pneumococcal vaccine franchise, COVID-19 vaccine products developed with BioNTech, and a range of specialty medicines across oncology and cardiovascular/metabolic care. Pfizer also emphasizes its biosimilars platform and its global manufacturing strength.
Read moreShow less
From a competitive standpoint, Pfizer remains a large-scale leader in global pharma due to its breadth, pipeline depth, industrial footprint, and commercial reach. The company operates 36 manufacturing sites worldwide and sells products in about 200 countries and territories, giving it one of the broadest geographic footprints in the industry. That scale is strategically important in a sector where regulatory execution, manufacturing reliability, and access to markets are critical to sustaining long-term growth.
Recent developments underscore Pfizer’s focus on pipeline execution and portfolio optimization. In its May 5, 2026 quarterly update, the company reported solid first-quarter results and reaffirmed its 2026 guidance. Pfizer also highlighted recent regulatory and clinical progress, including European approval for HYMPAVZI in hemophilia with inhibitors and positive advances for ELREXFIO in relapsed or refractory multiple myeloma. These updates suggest that management is working to offset patent-expiry pressure and legacy COVID-related normalization with new launches and late-stage pipeline assets.
For investors, Pfizer offers a combination of defensive qualities and growth optionality: a large diversified franchise, a strong global manufacturing base, a well-known brand in vaccines and specialty medicines, and a pipeline intended to support the post-LOE period. As a U.S.-listed company on the NYSE, Pfizer remains a key reference name in large-cap healthcare exposure.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
